SCHEMBL6691722

SCHEMBL6691722

Cc1ccc(-c2nc(NC(=N)N)nc3c(F)cc(Cl)cc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.41
RPS6KA3 P51812 3/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
MAPT P10636 1/20 0.33
ADORA2A P29274 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
TP53 P04637 1/20 0.33
F9 P00740 1/20 0.33
F11 P03951 1/20 0.33
F7 P08709 1/20 0.33
ADORA1 P30542 1/20 0.33
APP P05067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6696503 0.89 HSP90AB1 (0.41) HSP90AB1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6695182 0.81 HSP90AB1 (0.61) HSP90AB1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6696024 0.77 MAPT (0.46) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL6695082 0.76 KDM4E (0.46) HSP90AB1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6691724 0.76 RAD52 (0.50) HSP90AB1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6698066 0.75 HSP90AB1 (0.41) HSP90AB1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6701729 0.75 ADORA2A (0.57) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL6700265 0.74 MAPT (0.46) HSP90AB1KDM4EALDH1A1KMT2AGAA
SCHEMBL6701160 0.74 MAPT (0.54) HSP90AB1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6696127 0.73 MAPT (0.59) HSP90AB1KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US claimed
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US disclosed
EP-1274691-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GmbH (DE) 2003-01-15 EP disclosed
WO-2001079186-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GMBH (DE) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors NHERF1, SLC9A3, SLC9A1 HSP90AB1 1039/4885RPS6KA3 2676/4885KDM4E 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.